Efficacy Study of Oral Collagen Peptide on Skin Conditions
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Skin firmness
研究概览
简要总结
To assess if oral intake of collagen peptide can improve skin conditions such as skin thickness, density and firmness.
详细描述
This is an one site, randomized, double-blind controlled clinical trial to assess the oral supplement of LISAVEI collagen peptide solid beverage on skin ageing improvement. Study product with collagen peptide and placebo product without collagen were randomly assigned to 90 eligible participants enrolled according to the inclusion and exclusion criteria. They took the assigned product once daily dissolved in 100 ml warm water for 12 weeks with 4-week regression phase(without intake of the test products), and visit the study site in Shanghai for four times(before starting the treatment, after 8 and 12 weeks, and 4 weeks after the last intake). Skin measurements including skin firmness, skin density, skin hydration and skin barrier were carried out at each visit with professional equipment and imaging system. Data were analyzed to validate if the administration of the test collagen peptide solid beverage will improve skin aging parameters such as firmness, thickness, density, hydration and skin barrier compared to placebo. The lasting effect was also observed by comparing between the two groups after 4-week regression time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 35 Years 至 55 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Healthy female adults aged between 35-55 years old
- •With fine wrinkles and skin laxity
- •Personal informed consents to participate in the study
- •Agree to keep their daily skincare routine unchanged for the duration of the study
- •Maintain good sun protection habits
- •Agree to refrain from wearing make-up on the face on the each study visit
排除标准
- •Female who is pregnant or nursing or planning to become pregnant during the course of the study
- •Individuals who are in the perimenopausal stage.
- •BMI<18.5 or BMI >27.9
- •Individuals suffering from chronic systemic diseases such as cardiovascular, cerebrovascular, liver, and kidney diseases.
- •Individuals who have diabetes.
- •Individuals suffering from skin conditions such as psoriasis, eczema, atopic dermatitis, and severe acne.
- •Individuals with depression or sleep disorders, those who smoke, and those who abuse alcohol.
- •Individuals who are using hormonal drugs, medications for obesity, absorption inhibitors, antidepressants, or appetite suppressants.
- •Individuals who have used hormones or anti-inflammatory drugs on their face and upper arms within the past two months.
- •Individuals who received facial laser therapy, chemical peeling or UV overexposure in the past 3 months
- •Individuals who can not avoid prolonged exposure to sunlight.
- •Individuals who are currently participating in other clinical studies or trials.
结局指标
主要结局
Skin firmness
时间窗: before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
The changes of skin firmness parameter tested by Cutometer MPA580
Skin thickness
时间窗: before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
The changes of skin thickness （μm） tested by Ultrascan UC 22
Skin density
时间窗: before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase)
The changes of skin density tested by Ultrascan UC 22
次要结局
- Skin hydration(before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase))
- Skin barrier(before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase))
- Facial image(before product treatment (T 0), after 8 weeks(T 1)and 12 weeks(T 2) of daily product intake, 4 weeks after the last intake(T 3, 4-week regression phase))